BridgeBio Oncology Therapeutics, Inc. (BBOT) said the U.S. Food and Drug Administration has granted Fast Track designation to BBO-11818 for the treatment of adults with advanced KRAS-mutant pancreatic ductal adenocarcinoma.
The designation follows preliminary data released in January 2026, in which BBO-11818 monotherapy showed a confirmed partial response in pancreatic cancer patients.
The company said anti-tumor activity was observed across dose levels and tumor types, with tumor reductions at higher doses and a generally favorable and differentiated safety profile during dose escalation.
BBO-11818 is currently being evaluated in the Phase I KONQUER-101 trial in patients with locally advanced unresectable or metastatic KRAS-mutant solid tumors, with updated data expected in the second half of 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.